Group 1 - Recent updates regarding TransMedics (TMDX) have been discussed in a video format [1] - The stock price of TransMedics was noted to be down by 2.36% on December 10, 2024 [2]

Group 1 - TransMedics (NASDAQ: TMDX) shares have decreased by 60% from their peak in August [2] - The stock experienced a decline prior to the Q3 earnings report and fell further after missing revenue estimates for Q3 [2] - The company has maintained its full-year revenue guidance despite the earnings miss [2] Group 2 - The article emphasizes the importance of tracking portfolio and watchlist stocks closely for potential investment opportunities [1] - The Growth Stock Forum offers a model portfolio of 15-20 stocks and a top picks list of up to 10 stocks expected to perform well [1]

Core Insights - TransMedics' shares fell by 14% following a positive announcement regarding the hiring of a new CFO, due to tempered revenue expectations for 2024 [1][2] - The company now projects 2024 revenue between $428 million and $432 million, indicating a growth of 77% to 79% compared to the previous year, which is lower than prior guidance [2][3] - Following a disappointing Q3 earnings report, where the company maintained market share but did not grow as expected, investors were looking for a rebound in Q4 [3] Financial Performance - The new guidance suggests a 35% sales growth rate for Q4, significantly lower than the triple-digit growth rates seen in 10 of the last 11 quarters [3] - TransMedics' shares have decreased by 59% from their highs, trading at 6.3 times sales, the lowest since going public in 2019 [4] Market Position and Future Outlook - Despite the slowdown in growth, TransMedics remains a leader and first mover in the organ transplant industry [4] - An analyst day is scheduled for December 10, which is expected to provide new insights and guidance for the company moving forward [5]

Leadership Transition - TransMedics Group, Inc. appointed Mr. Gerardo Hernandez as Chief Financial Officer effective December 2, 2024, succeeding Mr. Stephen Gordon [1] - Mr. Gordon will remain a non-executive employee until March 31, 2025, and will serve as a non-employee senior advisor until March 31, 2026 [1][4] Executive Background - Mr. Hernandez has over 25 years of experience in finance, primarily in healthcare and consumer packaged goods sectors [3] - He previously served as Vice President Finance at Alnylam Pharmaceuticals and held significant roles at Shire, including leading corporate FP&A during its acquisition by Takeda for $62 billion [3] Financial Outlook - TransMedics updated its 2024 revenue guidance to a range of $428 million to $432 million, indicating a year-over-year growth of 77% to 79% [5][4] Upcoming Events - The management team will participate in the Piper Sandler Conference on December 3, 2024, and the TransMedics Investor & Analyst Day on December 10, 2024 [2][8]

Core Viewpoint - TransMedics Group (TMDX) is a significant player in organ transplant therapy, but its premium valuation raises concerns in the current market context [1] Group 1: Company Performance - TMDX's shares have declined by 52.3% over the past three months, underperforming the Medical – Instruments sector's decline of 4% and the S&P 500's gain of 7.1% [3] - Despite a reported 64% revenue growth in Q3, TMDX's performance fell short of expectations by 4.8%, with earnings per share (EPS) of 12 cents missing market expectations by 57.1% [6] - The company has maintained its full-year revenue guidance of $425-$445 million, anticipating a recovery in the U.S. transplant market despite recent lower-than-expected sales [7] Group 2: Market Conditions - The U.S. transplant market has shown softness, leading to declining volumes for TMDX in recent quarters [6] - TMDX's gross margin contracted by 500 basis points to 56% in Q3 compared to the previous year, indicating rising costs that may persist [8] Group 3: Competitive Landscape - TMDX holds a competitive advantage with its warm physiologic portable technology for organ preservation, which outperforms competitors like Xvivo in terms of storage duration [12] - The company plans to launch its own OCS cold perfusion technology for the heart, further enhancing its competitive edge [12] Group 4: Future Outlook - The Zacks Consensus Estimate for TMDX's 2024 earnings is $1.00 per share, reflecting a projected year-over-year improvement of nearly 230%, although estimates have declined by 18% over the past 60 days [10] - Current market conditions and potential regulatory changes with a new U.S. President may impact TMDX's future sales and profit margins [9]

ANDOVER, Mass., Nov. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it will host an Investor & Analyst Day in New York City on Tuesday, December 10, 2024, at 10:00 AM ET.Waleed Hassanein, MD., President and Chief Executive Officer, and members of the leadership team will present an overview of TransMedics' growth strateg ...

Group 1 - The growth stock TransMedics (TMDX) has been on the watchlist and may soon be included in the investment portfolio [1] - Recent updates regarding TransMedics are discussed in a video, indicating potential interest from investors [1] Group 2 - Stock prices referenced were from the trading day of November 22, 2024, with the video published on November 24, 2024 [2]

Core Insights - TransMedics Group, Inc. is participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:00 p.m. ET [1][2] Company Overview - TransMedics is a leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation, headquartered in Andover, Massachusetts [3] - The company was founded to address the unmet need for more and better organs for transplantation, developing technologies to preserve organ quality and assess organ viability prior to transplant [3]

Group 1 - TransMedics Group, Inc. (NASDAQ: TMDX) has experienced significant stock volatility, with a 300% increase over a one-year period followed by a decline of approximately 50% after Q3 earnings due to a slight revenue miss [1] - MMMT Wealth, managed by Oliver, focuses on investment strategies and stock analysis, aiming to provide insights based on investor calls, presentations, and financials with a 3-5 year investment horizon [1] - Oliver has 5 years of investing experience and 4 years as a CPA, emphasizing the importance of thorough research in identifying high-potential businesses [1]

TransMedics (TMDX) reported $108.76 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 63.7%. EPS of $0.12 for the same period compares to -$0.12 a year ago.The reported revenue represents a surprise of -4.78% over the Zacks Consensus Estimate of $114.22 million. With the consensus EPS estimate being $0.28, the EPS surprise was -57.14%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to d ...